ArticleEuropean journal of nuclear medicine and molecular imaging2022
Imaging PARP with [
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026Review
- DNA damage response inhibitors in pancreatic cancer: progress and challenges.Frontiers in oncology · 2026Review
- Development and evaluation of aEJNMMI radiopharmacy and chemistry · 2025Article
- Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging.EJNMMI radiopharmacy and chemistry · 2025Review
- Recent Advances in Small Molecular PET Tracers for Pancreatic Cancer Diagnosis: Preclinical Stage.Mini reviews in medicinal chemistry · 2025Review
- Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape.Neuro-oncology · 2024Review
- An Optimized Liquid Chromatography-Mass Spectrometry Method for Ganglioside Analysis in Cell Lines.Cells · 2024Article
- [Journal of clinical medicine · 2024Review
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs.Molecules (Basel, Switzerland) · 2023Review
- Targeted Alpha-Particle Therapy: A Review of Current Trials.International journal of molecular sciences · 2023Review
- PET imaging of PARP expression usingEuropean journal of nuclear medicine and molecular imaging · 2023Article
- Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [EJNMMI research · 2022Article
- [Radiology. Imaging cancer · 2022Article
- Preclinical studies of a PARP targeted, Meitner-Auger emitting, theranostic radiopharmaceutical for metastatic ovarian cancer.Nuclear medicine and biologyArticle
Corrections and comments
- Commented on by[2022
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeRucaparib, an FDA-approved PARP inhibitor, is used as a single agent in maintenance therapy to provide promising treatment efficacy with an acceptable safety profile in various types of BRCA-mutated cancers. However, not all patients receive the same benefit from rucaparib-maintenance therapy. A predictive biomarker to help with patient selection for rucaparib treatment and predict clinical benefit is therefore warranted. With this aim, we developed [
methodWe incorporated the positron-emitting
resultsUptake of [
conclusionTaken together, we demonstrate the potential of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.